

Noxxon Pharma AG Therapeutic and Overview Pipeline Review H2

Noxxon Pharma AG Treatment Pipeline Review H2 2016

PUNE, INDIA, November 14, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development by [Noxxon Pharma AG](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/740533-noxxon-pharma-ag-product-pipeline-review-2016> □

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Noxxon Pharma AG
- The report provides overview of Noxxon Pharma AG including its business description, key facts, and locations and subsidiaries

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Noxxon Pharma AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Noxxon Pharma AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Noxxon Pharma AG's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Noxxon Pharma AG
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Noxxon Pharma AG's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Noxxon Pharma AG Snapshot 5

Noxxon Pharma AG Overview 5

Key Facts 5

Noxxon Pharma AG - Research and Development Overview 6

Key Therapeutic Areas 6

Noxxon Pharma AG - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Noxxon Pharma AG - Pipeline Products Glance 11

Noxxon Pharma AG - Clinical Stage Pipeline Products 11

Phase II Products/Combination Treatment Modalities 11

Phase I Products/Combination Treatment Modalities 12

Noxxon Pharma AG - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Noxxon Pharma AG - Drug Profiles 14
emapticap pegol - Drug Profile 14
Product Description 14
Mechanism Of Action 14
R&D Progress 14
lexaptepid pegol - Drug Profile 16
Product Description 16
Mechanism Of Action 16
R&D Progress 16
NOXD-19 - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
NOXD-20 - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
NOXD-21 - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
NOXG-15 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
NOXG-16 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
NOXL-41 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
NOXS-93 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
olaptosed pegol - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26

Access Report @ <https://www.wiseguyreports.com/reports/740533-noxxon-pharma-ag-product-pipeline-review-2016>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/353796142>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.